



# PLI scheme: Unlocking pharmaceutical sector's growth potential



Production Linked Incentive (PLI) scheme for the pharmaceutical sector



### **Overview**


#### **Objectives**

- Enhance India's manufacturing capabilities by increasing investment
- · Contribute to product diversification

#### The scheme would largely promote

- Development of complex and high-tech products
- Production of high value products in the country and increase the value addition in exports
- Employment for both skilled and unskilled personnel

### Scheme coverage



\*GMR refers to Global Manufacturing Revenue of Pharmaceutical goods for FY 2019-20

\*\* It includes one year for application process (FY 21), one-year optional gestation period (FY 22), six years incentive period (FY 23-28) and one year for incentive disbursement for (FY 28-29).

# Key highlights

Cover maximum players of the industry	Base year for calculation of incremental sales to be FY 2019-20	<ul><li>Selection of applicant based on pre- defined criteria to assess-</li><li>Experience</li><li>Capacity to grow</li><li>Capacity to innovate</li></ul>
Incentive per participant to be	Participants may avail of up to one	Incentive will be paid for a
subject to ceilings to be specified in	year of gestation period from the	maximum period of 6 years for each
scheme guidelines	date of approval	participants

Scheme guidelines laying down important details such as evaluation criteria, ceiling per applicant, application procedure, timelines are yet to be notified by the department

### Category of goods and incentive rate

Category of goods	Products covered	Rates	Year
Category 1	Biopharmaceutical: Complex generic drugs; patented drugs or drugs nearing patent expiry; cell-based or gene therapy drugs; orphan drugs; special empty capsules like HPMC, pullulan, enteric, etc.; complex excipients; phytopharmaceuticals; other drugs as approved	10% of incremental sales	First 4 years
		8% of incremental sales	5 <sup>th</sup> year
		6% of incremental sales	6 <sup>th</sup> year
Category 2	Active Pharmaceutical Ingredients/Key starting materials/drug intermediates	10% of incremental sales	First 4 years
		8% of incremental sales	5 <sup>th</sup> year
		6% of incremental sales	6 <sup>th</sup> year
Category 3	Repurposed drugs; autoimmune drugs, anti- cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs; in vitro diagnostic devices; other drugs as approved; other drugs not manufactured in India	5% of incremental sales	First 4 years
		4% of incremental sales	5 <sup>th</sup> year
		3% of incremental sales	6 <sup>th</sup> year



# **Eligibility for incentive**

Applicant's group	Minimum cumulative investment per participant (INR crore)	Minimum percentage growth in sales (year-on-year)	
Α	INR 1,000 crore over 5 years FY 2021-22: 200 FY 2022-23: 400 FY 2023-24: 600 FY 2024-25: 800 FY 2025-26: 1000	For first year of production, participants shall have to achieve minimum threshold sales which will be specified by value for each group in the scheme guidelines. For subsequent years, the participants will have to achieve a minimum percentage growth of 7% year-on-year.	
В	INR 250 crore over 5 years FY 2021-22: 50 FY 2022-23: 100 FY 2023-24: 150 FY 2024-25: 200 FY 2025-26: 250		
C	INR 50 crore over 5 years FY 2021-22: 10 FY 2022-23: 20 FY 2023-24: 30 FY 2024-25: 40 FY 2025-26: 50		

For MSME participants, the threshold minimum cumulative investment shall be as committed by the participant in application form

<sup>4</sup> PLI scheme: Unlocking Pharmaceutical sector's growth potential

# How can we help?



#### **Evaluate eligibility**

- Minimum revenue and cumulative investment
- Manufacture of notified product
- Minimum percentage growth in sales



#### **Application preparation**

Review and collate requisite documents/ information/simulations/projections to prepare application



#### **Filing of application**

Assist in filing application before the Department of Pharmaceuticals



#### Replies to queries raised by the government/ nodal agency

- Preparation of additional replies and queries
- Representation before the government/nodal agency



## Follow-up with government authorities and nodal agency

- Follow-up post filing of application
- Conduct meeting



#### **Periodical review**

Assist in periodic review of eligibility conditions under the scheme after filing the application



#### **Disbursement of funds**

Assist in obtaining the claim on the best effort basis



### **Our experts**

Grant Thornton Bharat delivers the greatest value by collaborating across services to create innovative and tailored solutions to resolve the clients' complex challenges.

#### Our sector experts span forecasting, business planning, government liasoning etc.



Amit Kumar Bajaj Partner and Sector leader, Pharma E: amit.bajaj@in.gt.com M: +91 9619709016



Krishan Arora Partner, Tax E: krishan.arora@in.gt.com M: +91 9818341530



Rahul Kapur Partner, Growth E: rahul.kapur@in.gt.com M: +91 9811210501



Kunal Sood Partner, Public Sector E: kunal.sood@in.gt.com M: +91 9971199600



Karan Kakkar Associate Partner, Tax E: karan.kakkar@in.gt.com M: +91 9650001762



Sachin Sharma Director, Tax E: sachin.sharma@in.gt.com M: +91 9910848085

# Contact us

#### **NEW DELHI**

National Office, Outer Circle, L 41, Connaught Circus, New Delhi - 110001 T +91 11 4278 7070

#### CHENNAI

9th Floor, Prestige Polygon, 471, Anna Salai, Mylapore Division, Teynampet, Chennai - 600018 T +91 44 4294 0000

**KOLKATA** 10C Hungerford Street, 5th Floor, Kolkata - 700017 T +91 33 4050 8000 **NEW DELHI** 6th Floor, Worldmark 2, Aerocity, New Delhi - 110037 T +91 11 4952 7400

#### DEHRADUN Suite No 2211, 2nd Floor, Building 2000, Michigan Avenue, Doon Express Business Park, Subhash Nagar, Dehradun -248002 T +91 135 2646 500

MUMBAI 11th Floor, Tower II, One International Center, SB Marg Prabhadevi (W), Mumbai - 400013 T +91 22 6626 2600

Nehru Nagar,

AHMEDABAD

Nr Azad Society,

Ahmedabad - 380015

Chambers

7th Floor, Heritage

GURGAON 21st Floor, DLF Square, Jacaranda Marg, DLF Phase II, Gurgaon - 122002 T +91 124 462 8000

MUMBAI Kaledonia, 1st Floor, C Wing, (Opposite J&J Office), Sahar Road, Andheri East, Mumbai <u>- 400 069</u> BENGALURU

5th Floor, 65/2, Block A, Bagmane Tridib, Bagmane Tech Park, CV Raman Nagar, Bengaluru - 560093 T+91 80 4243 0700

HYDERABAD 7th Floor, Block III, White House, Kundan Bagh, Begumpet, Hyderabad - 500016 T +91 40 6630 8200

**NOIDA** Plot No 19A, 2nd Floor, Sector - 16A, Noida - 201301 T +91 120 485 5900

#### CHANDIGARH

B-406A, 4th Floor, L&T Elante Office Building, Industrial Area Phase I, Chandigarh - 160002 T +91 172 4338 000

#### KOCH

6th Floor, Modayil Centre Point, Warriam Road Junction, MG Road Kochi - 682016 T +91 484 406 4541

#### PUNE

3rd Floor, Unit No 309-312, West Wing, Nyati Unitree, Nagar Road, Yerwada Pune - 411006 T +91 20 6744 8800

### For more information or for any queries, write to us at gtbharat@in.gt.com



#### Follow us @GrantThorntonIN

© 2021 Grant Thornton Bharat LLP. All rights reserved.

"Grant Thornton Bharat" means Grant Thornton Advisory Private Limited, the sole member firm of Grant Thornton International Limited (UK) in India, and those legal entities which are its related parties as defined by the Companies Act, 2013, including Grant Thornton Bharat LLP.

Grant Thornton Bharat LLP, formerly Grant Thornton India LLP, is registered with limited liability with identity number AAA-7677 and has its registered office at L-41 Connaught Circus, New Delhi, 110001.

References to Grant Thornton are to Grant Thornton International Ltd. (Grant Thornton International) or its member firms. Grant Thornton International and the member firms are not a worldwide partnership. Services are delivered independently by the member firms.